Abstract
Nonalcoholic fatty liver disease (NAFLD) affects about 20%-30% of the general population, and its clinical relevance arises from the fact that 20%-30% of these subjects develop non-alcoholic steatohepatitis (NASH), a condition at risk of cirrhosis progression. In addition NAFLD, and in particular NASH patients, are also at high risk of cardiovascular alterations, suffering overall from an increased liver and no liver-related events of risk and death. At the moment liver biopsy is the gold standard for a correct evaluation of NASH and fibrosis among NAFLD patients. However, the high and increasing prevalence of NAFLD has triggered an intensive search for alternative and non-invasive methods for evaluating disease severity. Specifically we can distinguish two main groups of non-invasive methodologies, namely ‘serum markers’ that use clinical and/or biochemical variables, and methodologies derived from elaboration of parameters arising from liver imaging techniques. All these tools showed encouraging results, even though their utility in clinical practice in the individual patients is still under debate. Therefore further efforts are needed in order to generate non-invasive algorithms that correctly assess liver damage in NAFLD patients. In particular, it should be interesting to perform gender-specific analysis, by combining old and new tools, with the aim to generate more accurate scores. Finally we think that non-invasive scores should not only be able to correctly classify the severity of liver disease in NAFLD patients, but also predict liver and non-liver related morbidity and mortality, further acting as time-dependent markers of liver and systemic disease activity. This review summarizes the present knowledge on noninvasive diagnosis in NAFLD patients, and suggest future directions for this complex research area.
Current Pharmaceutical Design
Title:Non Invasive Indexes for the Assessment of Patients with Non-alcoholic Fatty Liver Disease
Volume: 19 Issue: 29
Author(s): Salvatore Petta, Aase Handberg and Antonio Craxi
Affiliation:
Keywords: HCV, STEATOSIS, CD36.
Abstract: Nonalcoholic fatty liver disease (NAFLD) affects about 20%-30% of the general population, and its clinical relevance arises from the fact that 20%-30% of these subjects develop non-alcoholic steatohepatitis (NASH), a condition at risk of cirrhosis progression. In addition NAFLD, and in particular NASH patients, are also at high risk of cardiovascular alterations, suffering overall from an increased liver and no liver-related events of risk and death. At the moment liver biopsy is the gold standard for a correct evaluation of NASH and fibrosis among NAFLD patients. However, the high and increasing prevalence of NAFLD has triggered an intensive search for alternative and non-invasive methods for evaluating disease severity. Specifically we can distinguish two main groups of non-invasive methodologies, namely ‘serum markers’ that use clinical and/or biochemical variables, and methodologies derived from elaboration of parameters arising from liver imaging techniques. All these tools showed encouraging results, even though their utility in clinical practice in the individual patients is still under debate. Therefore further efforts are needed in order to generate non-invasive algorithms that correctly assess liver damage in NAFLD patients. In particular, it should be interesting to perform gender-specific analysis, by combining old and new tools, with the aim to generate more accurate scores. Finally we think that non-invasive scores should not only be able to correctly classify the severity of liver disease in NAFLD patients, but also predict liver and non-liver related morbidity and mortality, further acting as time-dependent markers of liver and systemic disease activity. This review summarizes the present knowledge on noninvasive diagnosis in NAFLD patients, and suggest future directions for this complex research area.
Export Options
About this article
Cite this article as:
Petta Salvatore, Handberg Aase and Craxi Antonio, Non Invasive Indexes for the Assessment of Patients with Non-alcoholic Fatty Liver Disease, Current Pharmaceutical Design 2013; 19 (29) . https://dx.doi.org/10.2174/1381612811319290004
DOI https://dx.doi.org/10.2174/1381612811319290004 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Assessment of Coronary Microcirculation with Myocardial Contrast Echocardiography
Current Pharmaceutical Design Magnesium and Anaesthesia
Current Drug Targets Diabetes and Vascular Disease: Basic Concepts of Nitric Oxide Physiology, Endothelial Dysfunction, Oxidative Stress and Therapeutic Possibilities
Current Vascular Pharmacology Subject Index To Volum 2
Current Diabetes Reviews Antihypertensive Therapy: Role of Aldosterone Antagonists
Current Pharmaceutical Design Statins and Carotid Intima-Media Thickness Reduction: An Up-to-Date Review
Current Medicinal Chemistry Radioprotective Effects of Plants from the Lamiaceae Family
Anti-Cancer Agents in Medicinal Chemistry Prediction Models and Scores in Adult Congenital Heart Disease
Current Pharmaceutical Design Metabolic Syndrome and Cardiometabolic Risk Factors
Current Vascular Pharmacology The Evil Axis of Obesity, Inflammation and Type-2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Structural MRI Predictors of Late-Life Cognition Differ Across African Americans, Hispanics, and Whites
Current Alzheimer Research Chronic Coronary Syndrome: Overcoming Clinical Practice Guidelines. The role of the COMPASS Strategy
Current Cardiology Reviews The Dialogue Between Endothelial Cells and Monocytes/Macrophages in Vascular Syndromes
Current Pharmaceutical Design Anti-Inflammatory Approaches to Reduce Acute Cardiovascular Events: Not Only Benefits
Current Pharmaceutical Biotechnology Biocatalysis in the Pharmaceutical Industry. A Greener Future
Current Green Chemistry Membrane Lipids in the Function of Serotonin and Adrenergic Receptors
Current Medicinal Chemistry Influences of Maternal Nutritional Status on Vascular Function in the Offspring
Current Drug Targets Gender Specific Aspects of Cell Death in the Cardiovascular System
Current Pharmaceutical Design Advances in Stem Cells Transplantation for the Therapy of Parkinson’s Disease
Current Stem Cell Research & Therapy ENaC Regulation by Proteases and Shear Stress
Current Molecular Pharmacology